You are viewing: Spain Biobanking Market analysis
Part of: Biobanking Market (Global)

The Spain Biobanking Market was valued at $95.2 Million in 2025 and projected to reach to $137.9 Million by 2030, representing a compound annual growth rate of 7.7%. Spain's biobanking market is positioned for steady expansion through 2030, supported by increasing healthcare investments and the nation's focus on precision medicine.

Spain Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Spain Biobanking Market Trends and Insights

  • This 7.7% compound annual growth rate reflects Spain's increasing investment in healthcare infrastructure and precision medicine initiatives.
  • Spain's biobanking sector is driven by rising demand for personalized treatment options and enhanced diagnostic capabilities across Spanish healthcare institutions. The Spanish biobanking landscape is characterized by growing collaboration between public research institutions and private healthcare providers.
  • Spain's commitment to advancing genomic research and clinical trials has positioned the country as a key player in European biobanking development.
  • By 2030, Spain is expected to see significant expansion in sample collection, storage, and data management capabilities, supported by regulatory frameworks and funding from both national and European sources. Spain's biobanking market benefits from its aging population and increasing prevalence of chronic diseases, which drive the need for comprehensive biological sample repositories.
  • Spain's healthcare system's modernization efforts and integration of digital technologies are further accelerating market growth through improved sample tracking and accessibility for research purposes..

Key Market Statistics

  • CAGR (2025-2030) 7.7% CAGR
  • Market Size, 2025 ~USD 95.2 Million
  • Forecast, 2030 ~USD 137.9 Million
  • Country Spain

Spain Biobanking Market Overview

Market Valuation Growth :

Spain's biobanking market is valued at $95.2 million in 2025, with projections reaching $137.9 million by 2030, representing a robust 7.7% CAGR driven by healthcare modernization.

Precision Medicine Adoption :

Spanish healthcare institutions are increasingly investing in precision medicine initiatives, creating strong demand for advanced biobanking infrastructure and sample management solutions.

Healthcare Infrastructure Investment :

Spain's commitment to upgrading healthcare infrastructure supports biobanking expansion, with government and private sector funding accelerating facility development and technological adoption.

Diagnostic Capability Enhancement :

Rising demand for personalized treatment options is driving Spanish hospitals and research centers to expand biobanking capabilities for improved diagnostic accuracy and patient outcomes.

Spain Biobanking Market Dynamics

  • The 7.7% CAGR reflects growing adoption among Spanish hospitals, research institutions, and diagnostic centers seeking to enhance personalized treatment capabilities.
  • Government initiatives promoting healthcare digitalization and genomic research are expected to accelerate market penetration. The Spanish biobanking sector will benefit from rising patient awareness of personalized medicine and regulatory frameworks supporting sample collection and storage.
  • Collaboration between public healthcare systems and private research organizations will drive innovation in biobanking technologies.
  • By 2030, Spain's market is anticipated to mature with increased standardization, improved data management systems, and expanded applications in clinical diagnostics and pharmaceutical research..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Spain's biobanking market is valued at $95.2 million in 2025 and is forecast to reach $137.9 million by 2030, representing a 7.7% CAGR.
    • Spain's healthcare modernization and precision medicine initiatives are primary drivers of biobanking market expansion.
    • Spain's aging population and rising chronic disease prevalence create sustained demand for biological sample repositories.
    • Spain's collaborative ecosystem between public research institutions and private healthcare providers strengthens market competitiveness.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    Spain Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    SPAIN: BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS68.469.773.678.784.591.298.8107.57.9
    CROS20.320.521.622.924.426.228.230.57.2
    TOTAL88.790.395.2101.5108.9117.4127137.97.7

    SPAIN: BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES9.29.410.211.112.113.314.6169.5
    HOSPITALS & DIAGNOSTIC LABORATORIES5.75.86.36.87.48.18.89.79
    PHARMA-BIOTECH COMPANIES & CROS21.922.524.326.629.13235.238.99.8
    TOTAL36.837.840.844.448.653.358.664.59.6

    Target Audience

    • Biobanking Solution Providers : Companies offering biobanking software, storage systems, and sample management solutions need Spain-specific market data to assess demand, identify customer segments, and plan product localization strategies.
    • Healthcare Investment Firms : Private equity and venture capital investors require detailed Spain market analysis to evaluate biobanking investment opportunities, growth potential, and exit strategies within the Spanish healthcare sector.
    • Pharmaceutical & Diagnostics Companies : Pharma and diagnostics firms expanding in Spain need biobanking market insights to understand sample availability, research collaboration opportunities, and precision medicine adoption rates.
    • Spanish Healthcare Institutions : Hospitals, research centers, and diagnostic labs in Spain require market benchmarking data to justify biobanking investments, evaluate technology solutions, and align with national healthcare trends.
    • Market Research & Consulting Firms : Research organizations and consultants need comprehensive Spain biobanking data to support client advisory services, competitive analysis, and strategic recommendations for healthcare stakeholders.

    Key Companies in the Spain Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for Spain's biobanking market ($95.2M in 2025) with verified 7.7% CAGR forecasts through 2030, enabling accurate business planning and investment decisions.
    • Competitive Landscape Intelligence : Understand Spain-specific market dynamics, key players, and competitive positioning within the Spanish biobanking sector to identify partnership and expansion opportunities.
    • Regulatory & Infrastructure Insights : Access detailed analysis of Spanish healthcare regulations, government initiatives, and infrastructure investments shaping biobanking adoption and compliance requirements.
    • Precision Medicine Opportunity Assessment : Evaluate demand drivers for personalized medicine in Spain, including hospital adoption rates and diagnostic capability gaps, to identify high-potential market segments.
    • Strategic Market Entry Planning : Leverage Spain-focused forecasts and market segmentation data to develop targeted go-to-market strategies, pricing models, and partnership frameworks for Spanish healthcare institutions.

    Frequently asked questions

    What is the current size of Spain's biobanking market?

    Spain's biobanking market is valued at $95.2 million in 2025 and is expected to grow to $137.9 million by 2030.

    What is the growth rate of Spain's biobanking market?

    Spain's biobanking market is growing at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2030.

    What factors are driving growth in Spain's biobanking sector?

    Spain's biobanking growth is driven by healthcare modernization, precision medicine adoption, an aging population, and increased chronic disease prevalence.

    How is Spain's biobanking market structured?

    Spain's biobanking market comprises public research institutions, private healthcare providers, and specialized biobanking facilities collaborating on sample collection and storage.

    What role does technology play in Spain's biobanking market?

    Digital technologies in Spain enable improved sample tracking, data management, and accessibility for research, accelerating market modernization and efficiency.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status